Hot Topics · Cross-industry
FDA Approval Pathway
510(k), PMA and De Novo clearance timing and regulatory friction.
AI-generated · informational only · not investment advice · verify before relying.
01 · The lede
Intelligence brief
SeventhBiz Intelligence
Refreshed 3h agoFDA approval pathways have shifted from routine regulatory gating to a structurally contested and bifurcated approval environment where regulatory discretion, novel modalities, and manufacturing compliance now determine which therapies reach market and which do not. The language arc moved from passive submission narratives (Q3 2026: 'we intend to submit') to active FDA engagement language and explicit acknowledgment of discretionary FDA gates (Q4 2026: 'pending regulatory alignment', 'subject to further discussion with the FDA', 'accelerated approval pathway based on FDA feedback').…
The full brief is part of the subscription
03 · Companies
Companies engaging with this topic
Tracked companies with an on-record signal on FDA Approval Pathway this cycle.
06 · Evidence
Recent mentions
Preview“For adults 65 years of age and older, accelerated approval was based on results from a separate randomized, observer-blind, active-controlled clinical trial... Clinical benefit in adults 65 years of age and older will be further assessed in a postmarketing confirmatory clinical trial.”
Business Highlights — FDA Approval and Commercial Launch of mFLUSIVA
“A decision on filing in United States subject to further discussion with the FDA.”
Stephen Hoge prepared remarks — Commercial portfolio update
“We expect to submit our Zio MCT filing to the FDA in 2027.”
CEO prepared remarks — Quentin Blackford
Unlock FDA Approval Pathway
The full intelligence brief, how the language shifted quarter over quarter, the bear case, and every company mention — verbatim and source-cited.